The efficacy and safety of combined treatments are evaluated in studies where drug combinations are compared with the gold standard treatment, which, according to the results of the MARINA⁽²¹) and ANCHOR⁽²²⁾ studies, consists of twelve consecutive monthly intravitreal injections of an antiangiogenic agent.

Use of this treatment regime led to outcomes of 90% in vision stabilization and approximately 30-40% of significant improvement after one year.